Two Additional Coronavirus Patients Treated at Leading New York Hospital with CytoDyn’s Leronlimab, Bringing the Total to Four Patients Mar 23, 2020 6:00am EDT
U.S. Food and Drug Administration (FDA) Grants Emergency IND for Two Coronavirus Patients Treated in New York with CytoDyn’s Leronlimab Mar 19, 2020 6:00am EDT
CytoDyn to Present at Wall Street Reporter’s NEXT SUPER STOCK - Live Stream Event on March 19, 2020 Mar 18, 2020 3:52pm EDT
CytoDyn Files Modified IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140) and Advises Correction to Press Release Issued on March 12, 2020 Mar 16, 2020 6:00am EDT
CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140) Mar 09, 2020 6:00am EDT
CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140) Mar 08, 2020 5:52pm EDT
CytoDyn Treats First Patient with Leronlimab in Phase 2 Trial for GvHD under Modified Trial Protocol Mar 04, 2020 6:00am EST
CytoDyn Reports Remarkable Outcomes for Additional Cancer Patients in mTNBC Trial; Following an Overwhelming Community Response, CytoDyn Expects to Enroll More Than 20 Patients in its 22 Solid Tumor Cancer Trial in the Next 60 Days Mar 02, 2020 6:00am EST
CytoDyn to Hold Conference Call for Updates on Filing Phase 2 Trial with FDA for Treatment of Coronavirus in U.S., Status of BLA, Breakthrough Therapy Designation, Basket Trial for 22 Solid Tumor Cancers and Licensing Opportunities in Several Countries Feb 28, 2020 1:28pm EST
